SebErb (Gefitinib) is available as 250 mg film coated tablet for oral administration.
Gefitinib INN 250 mg
FDA Approved Indications
SebErb (Gefitinib) is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected.
SebErb Tablet: Each commercial box contains 3×10’s tablets in Alu-Alu blister pack.